[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

IceCure Medical Ltd. (NASDAQ: ICCM) filed a Form 6-K on 25 June 2025 reporting that it has furnished a press release entitled “IceCure Announces Record Date for Rights Offering for Up to $10 Million.” The press release, provided as Exhibit 99.1, is incorporated by reference into the company’s existing registration statements on Forms F-3 (Nos. 333-258660 & 333-267272) and S-8 (Nos. 333-270982, 333-264578, 333-262620 & 333-281587). The filing contains no financial statements, earnings data or detailed terms of the rights offering.

The company indicates only that a record date has been set for shareholders to participate in a rights offering of up to $10 million. If completed, this capital raise would provide additional liquidity while allowing existing shareholders to maintain proportional ownership by exercising their rights. However, subscription price, ratio, and expected closing date are not disclosed in this document. The report was signed by Chief Executive Officer Eyal Shamir.

Positive

• Capital infusion potential: Planned rights offering could provide up to $10 million in additional funds, strengthening liquidity.
• Shareholder-friendly structure: Rights offering allows existing investors to maintain ownership percentage.

Negative

• Dilution risk: Issuing new shares may dilute non-participating shareholders once terms are set.
• Limited disclosure: Filing does not specify subscription price, ratio, or timeline, leaving uncertainty around financial impact.

Insights

Financial Analyst

TL;DR: Filing announces up to $10 M rights offering; capital positive, dilution risk neutral overall.

The 6-K merely furnishes notice of a forthcoming rights offering and embeds the related press release into existing shelf registrations. From a financing standpoint, raising up to $10 million can extend runway and fund operations without resorting to more expensive debt. Because rights offerings permit current holders to purchase additional shares, participation can mitigate ownership dilution. Nevertheless, the lack of disclosed pricing or ratios means investors cannot yet quantify dilution or subscription value. Overall impact is neutral until detailed terms emerge.

Corporate Governance Expert

TL;DR: Governance-wise, rights offering respects pre-emptive rights but signals funding need.

By choosing a rights offering, IceCure gives existing shareholders priority access to new shares, aligning with shareholder-friendly practices and avoiding preferential treatment of new investors. Incorporating the exhibit into all active registration statements maintains regulatory compliance and disclosure consistency. Still, announcing a capital raise highlights continuing capital requirements, which may concern investors about cash burn. Without timetable or pricing, transparency is partial, leaving stakeholders to await fuller disclosure.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: June 2025 (Report No. 2)

 

Commission File Number: 001-40753

 

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

 

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F             ☐ Form 40-F

 

 

 

 

 

 

CONTENTS

 

On June 25, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Announces Record Date for Rights Offering for Up to $10 Million,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

 

The press release attached herewith as Exhibit 99.1 is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit No.	 	 
99.1	 	Press release dated June 25, 2025 titled “IceCure Announces Record Date for Rights Offering for Up to $10 Million”

 

1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	ICECURE MEDICAL LTD.
 	 	 
Date: June 25, 2025	By:	/s/ Eyal Shamir
 	 	Name: 	Eyal Shamir
 	 	Title:	Chief Executive Officer

 

2 

 

FAQ

What did IceCure Medical (ICCM) disclose in its June 25 2025 Form 6-K?

The company announced the record date for a rights offering of up to $10 million and furnished the related press release as Exhibit 99.1.

How much does IceCure plan to raise through the rights offering?

Up to US$10 million.

Does the filing include pricing or ratio details of the rights offering?

No. The Form 6-K does not provide subscription price, rights ratio, or closing timeline.

Why is the press release incorporated into IceCure’s registration statements?

Incorporation ensures the rights offering disclosure becomes part of the company’s shelf and employee benefit registration documents.

Who signed the Form 6-K for IceCure Medical?

Chief Executive Officer Eyal Shamir.